Study Says Bird-Flu Vaccine Comparison Tests Vary Too Much
This article was originally published in PharmAsia News
A British study warns drug makers the tests they conduct to determine the effectiveness of their avian influenza vaccines may not be as true as previously thought. The study looked at the tests vaccine makers use and said the sensitivity of the tests varies according to values used. That, researchers said, could lead the pharmas to over- or under-estimate the effectiveness of their vaccine's smallest dose for protection when compared with a competitor. One expert said the study means an effort should be made to develop a consensus on the values to be measured in such tests. (Click here for more
You may also be interested in...
A nasal spray formulated using compounds already approved by regulatory bodies in Europe and the US can “prevent and slow” transmission of COVID-19, according to UK researchers who are now seeking a partner to commercialize the product.
Russia is promising the best of both worlds – a low price with a near-perfect efficacy. While the basic science is plausible, its best-in-class claims are bound to generate skepticism.
The Belgian biotech has divested its drug discovery services unit in Croatia which was making a nice profit but was not a priority as Galapagos concentrates on setting up its commercial operations in Europe.